Jupiter Topco LLC Purchases Shares of 68,500 Ocular Therapeutix, Inc. $OCUL

Jupiter Topco LLC bought a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 68,500 shares of the biopharmaceutical company’s stock, valued at approximately $672,000.

A number of other large investors have also recently added to or reduced their stakes in OCUL. BlackRock Inc. bought a new position in shares of Ocular Therapeutix in the 2nd quarter worth $190,278,000. Millennium Management LLC increased its stake in Ocular Therapeutix by 3,136.1% in the third quarter. Millennium Management LLC now owns 3,855,706 shares of the biopharmaceutical company’s stock valued at $45,073,000 after purchasing an additional 3,736,560 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in Ocular Therapeutix by 2,003.2% during the third quarter. Alliancebernstein L.P. now owns 3,424,439 shares of the biopharmaceutical company’s stock worth $40,032,000 after acquiring an additional 3,261,619 shares in the last quarter. Commodore Capital LP bought a new stake in shares of Ocular Therapeutix in the first quarter worth about $21,810,000. Finally, Vanguard Group Inc. raised its position in shares of Ocular Therapeutix by 26.3% during the fourth quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock worth $140,523,000 after purchasing an additional 2,411,953 shares during the period. 59.21% of the stock is currently owned by institutional investors.

Insider Transactions at Ocular Therapeutix

In related news, insider Jeffrey Heier sold 3,296 shares of Ocular Therapeutix stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $10.78, for a total transaction of $35,530.88. Following the completion of the sale, the insider directly owned 318,326 shares of the company’s stock, valued at approximately $3,431,554.28. This trade represents a 1.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Pravin Dugel sold 21,649 shares of the company’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $10.77, for a total value of $233,159.73. Following the completion of the transaction, the insider directly owned 2,525,429 shares in the company, valued at approximately $27,198,870.33. This represents a 0.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 29,877 shares of company stock worth $321,827. Company insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Wall Street Zen upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective (up from $21.00) on shares of Ocular Therapeutix in a research report on Thursday, June 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Friday, July 17th. Robert W. Baird boosted their price target on Ocular Therapeutix from $24.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $23.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, August 4th. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $25.75.

Ocular Therapeutix Price Performance

NASDAQ:OCUL opened at $10.64 on Monday. The company has a current ratio of 13.10, a quick ratio of 13.03 and a debt-to-equity ratio of 0.14. The firm has a fifty day simple moving average of $9.76 and a 200 day simple moving average of $9.22. The stock has a market capitalization of $2.34 billion, a PE ratio of -7.49 and a beta of 0.97. Ocular Therapeutix, Inc. has a 1-year low of $6.23 and a 1-year high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. The firm had revenue of $13.47 million for the quarter, compared to the consensus estimate of $13.20 million. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%.The business’s revenue was down .1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.39) earnings per share. On average, research analysts expect that Ocular Therapeutix, Inc. will post -1.47 EPS for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.